Journal Of Medicinal Chemistry SCIE

國際簡稱：J. Med. Chem. 參考譯名：藥物化學雜志

主要研究方向：醫(yī)學-醫(yī)藥化學非預(yù)警期刊審稿周期：約2.1個月

《藥物化學雜志》(Journal Of Medicinal Chemistry)是一本由American Chemical Society出版的以醫(yī)學-醫(yī)藥化學為研究特色的國際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評論文章和綜述文章，及時報道該領(lǐng)域相關(guān)理論、實踐和應(yīng)用學科的最新發(fā)現(xiàn)，旨在促進該學科領(lǐng)域科學信息的快速交流。該期刊是一本開放期刊，近三年沒有被列入預(yù)警名單。該期刊享有很高的科學聲譽，影響因子不斷增加，發(fā)行量也同樣高。

1區(qū) 中科院分區(qū)
Q1 JCR分區(qū)
922 年發(fā)文量
6.8 IF影響因子
開放是否OA
240 H-index
1959 創(chuàng)刊年份
Biweekly 出版周期
English 出版語言

The Journal of Medicinal Chemistry publishes studies that contribute to an understanding of the relationship between molecular structure and biological activity or mode of action.

Some specific areas that are appropriate include the following:

* Design, synthesis, and biological evaluation of novel biologically active compounds, diagnostic agents, or labeled ligands employed as pharmacological tools.

* Molecular modifications of reported series that lead to a significantly improved understanding of their structure-activity relationships (SAR). Routine extensions of existing series that do not utilize novel chemical or biological approaches or do not add significantly to a basic understanding of the SAR of the series will normally not be accepted for publication.

*Structural biological studies (X-ray, NMR, etc.) of relevant ligands and targets with the aim of investigating molecular recognition processes in the action of biologically active compounds.

* Molecular biological studies (e.g., site-directed mutagenesis) of macromolecular targets that lead to an improved understanding of molecular recognition.

*Computational studies that provide fresh insight into the SAR of compound series that are of current general interest or analysis of other available data that subsequently advance medicinal chemistry knowledge.

* Substantially novel computational chemistry methods with demonstrated value for the identification, optimization, or target interaction analysis of bioactive molecules.

* Effect of molecular structure on the distribution, pharmacokinetics, and metabolic transformation of biologically active compounds. This may include design, synthesis, and evaluation of novel types of prodrugs.

* Novel methodology with broad application to medicinal chemistry, but only if the methods have been tested on relevant molecules.

[ 查看全部 ]

投稿咨詢加急咨詢

Journal Of Medicinal Chemistry期刊信息

ISSN：0022-2623
出版語言：English
是否OA：開放
E-ISSN：1520-4804
出版地區(qū)：UNITED STATES
是否預(yù)警：否
出版商：American Chemical Society
出版周期：Biweekly
創(chuàng)刊時間：1959
開源占比：0.099
Gold OA文章占比：13.77%
OA被引用占比：0.0691...
出版國人文章占比：0.14
出版撤稿占比：0.0011...
研究類文章占比：98.81%

Journal Of Medicinal Chemistry CiteScore評價數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

12.8

1.986

1.594

學科類別	分區(qū)	排名	百分位
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Drug Discovery	Q1	13 / 157	92%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Molecular Medicine	Q1	24 / 178	86%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個指標。當年CiteScore 的計算依據(jù)是期刊最近4年（含計算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻數(shù)。例如，2022年的 CiteScore 計算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻數(shù)量注：文獻類型包括：文章、評論、會議論文、書籍章節(jié)和數(shù)據(jù)論文。

Journal Of Medicinal Chemistry中科院評價數(shù)據(jù)

中科院 2023年12月升級版

Top期刊	綜述期刊	大類學科		小類學科
是	否	醫(yī)學	1區(qū)	CHEMISTRY, MEDICINAL 藥物化學	1區(qū)

中科院 2022年12月升級版

Top期刊	綜述期刊	大類學科		小類學科
是	否	醫(yī)學	1區(qū)	CHEMISTRY, MEDICINAL 藥物化學	1區(qū)

中科院 2021年12月舊的升級版

Top期刊	綜述期刊	大類學科		小類學科
是	否	醫(yī)學	1區(qū)	CHEMISTRY, MEDICINAL 藥物化學	1區(qū)

中科院 2021年12月基礎(chǔ)版

Top期刊	綜述期刊	大類學科		小類學科
是	否	醫(yī)學	2區(qū)	CHEMISTRY, MEDICINAL 藥物化學	1區(qū)

中科院 2021年12月升級版

Top期刊	綜述期刊	大類學科		小類學科
是	否	醫(yī)學	1區(qū)	CHEMISTRY, MEDICINAL 藥物化學	1區(qū)

中科院 2020年12月舊的升級版

Top期刊	綜述期刊	大類學科		小類學科
是	否	醫(yī)學	1區(qū)	CHEMISTRY, MEDICINAL 藥物化學	1區(qū)

Journal Of Medicinal Chemistry JCR評價數(shù)據(jù)（2023-2024年最新版）

按JIF指標學科分區(qū)	收錄子集	分區(qū)	排名	百分位
學科：CHEMISTRY, MEDICINAL	SCIE	Q1	4 / 72	95.1%

按JCI指標學科分區(qū)	收錄子集	分區(qū)	排名	百分位
學科：CHEMISTRY, MEDICINAL	SCIE	Q1	1 / 72	99.31%

Journal Of Medicinal Chemistry歷年數(shù)據(jù)統(tǒng)計

影響因子

中科院分區(qū)

Journal Of Medicinal Chemistry中國學者發(fā)文選摘

1、Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small- cell Lung Cancer
Author: Pei, Junping; Wang, Guan; Wang, Aoxue; Wu, Chengyong; Pan, Xiaoli; Shuai, Wen; Bu, Faqian; Zhu, Yumeng; Wang, Yuxi; Ouyang, Liang; Li, Weimin

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. , Issue , pp. -. DOI: 10.1021/acs.jmedchem.3c00027
2、Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy
Author: Zhu, Chenyu; Ze, Shuyin; Zhou, Ronghui; Yang, Xinyu; Wang, Haojie; Chai, Xiaolei; Fang, Meimiao; Liu, Mingyao; Wang, Yonghui; Lu, Weiqiang; Xie, Qiong

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 4734-4754. DOI: 10.1021/acs.jmedchem.2c018604734J
3、Targeting Receptor-Interacting Protein Kinase 1 by Novel Benzothiazole Derivatives: Treatment of Acute Lung Injury through the Necroptosis Pathway
Author: Zhang, Xinqi; Han, Qianyu; Hou, Ruilin; Xu, Lijuan; Zhang, Wannian; Xing, Chengguo; Xue, Lei; Zhuang, Chunlin

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 5261-5278. DOI: 10.1021/acs.jmedchem.3c00197
4、Application and Study of ROCK Inhibitors in Pulmonary Fibrosis: Recent Developments and Future Perspectives
Author: Xie, Yuting; Yue, Lin; Shi, Yaojie; Su, Xingping; Gan, Cailing; Liu, Hongyao; Xue, Taixiong; Ye, Tinghong

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 4342-4360. DOI: 10.1021/acs.jmedchem.2c01753
5、Development of Son of Sevenless Homologue 1 (SOS1) Modulators To Treat Cancers by Regulating RAS Signaling
Author: Luo, Guangmei; Wang, Bingrui; Hou, Qiangqiang; Wu, Xiaoxing

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 4324-4341. DOI: 10.1021/acs.jmedchem.2c01729
6、Unsymmetrical Phosphodiesters as GPR84 Antagonists with High Blood Exposure for the Treatment of Lung Inflammation
Author: Li, Shao-Xian; Wang, Si-Wei; Chen, Lin-Hai; Zhang, Qing; Lu, Dan; Chen, Jing; Fang, You-Chen; Gu, Min; Xie, Xin; Nan, Fa-Jun

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 8, pp. 5820-5838. DOI: 10.1021/acs.jmedchem.3c00053
7、Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1
Author: Gallego, Rebecca A.; Bernier, Louise; Chen, Hui; Cho-Schultz, Sujin; Chung, Loanne; Collins, Michael; Del Bel, Matthew; Elleraas, Jeff; Jones, Cinthia Costa; Cronin, Ciaran N.; Edwards, Martin; Fang, Xu; Fisher, Timothy; He, Mingying; Hoffman, Jacqui; Huo, Ruiduan; Jalaie, Mehran; Johnson, Eric; Johnson, Ted W.; Kania, Robert S.; Kraus, Manfred; Lafontaine, Jennifer; Le, Phuong; Liu, Tongnan; Maestre, Michael; Matthews, Jean; McTigue, Michele; Miller, Nichol; Mu, Qiming; Qin, Xulong; Ren, Shijian; Richardson, Paul; Rohner, Allison; Sach, Neal; Shao, Li; Smith, Graham; Su, Ruirui; Sun, Bin; Timofeevski, Sergei; Tran, Phuong; Wang, Shuiwang; Wang, Wei; Zhou, Ru; Zhu, Jinjiang; Nair, Sajiv K.

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 4888-4909. DOI: 10.1021/acs.jmedchem.2c02038
8、Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers
Author: Qiu, Qianqian; Chi, Fanglian; Zhou, Daoguang; Xie, Zhancheng; Liu, Yunxiao; Wu, Hanyu; Yin, Ziyu; Shi, Wei; Qian, Hai

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. , Issue , pp. -. DOI: 10.1021/acs.jmedchem.3c00036